The Future of Healthcare
Evolving Trends and Venture Capital Insights
The healthcare landscape is witnessing transformative changes driven by technological advancements, increased venture investment, and shifting market demands. As healthcare embraces new technologies, understanding the interplay between innovation, investment, and market readiness becomes crucial.
It is exciting to see that healthcare investments have increased in the last six months; however, biotech companies are still reporting funding issues. Why is that?
To better understand the situation, I spoke to industry experts, each with a unique perspective on the forces shaping the next era of healthcare.
Here, we explore the most compelling emerging trends and how investors navigate this evolving terrain.
Current State of Healthcare
The healthcare landscape has seen unprecedented growth in technology adoption, significantly altering traditional healthcare delivery models. Innovations such as Telemedicine, AI-enhanced diagnostics, and personalized medicine are becoming more prevalent and driven by necessity and opportunity. The rapid adoption of Telemedicine is a clear indicator of the scalability and necessity of technology solutions in today's healthcare ecosystem.
The healthcare and biotech sectors received considerable global venture funding, amounting to $15.7 billion in the first quarter of 2024, making up 24% of all international financing (Crunchbase News). This underscores the sector's prominence in attracting venture capital relative to other industries.
Emerging Trends in Healthcare
Emerging trends in healthcare include the integration of artificial intelligence for diagnosis and treatment, the expansion of Telemedicine, personalized medicine through genomics, advancements in wearable health technology, and an increased focus on mental health. These innovations aim to enhance patient care and healthcare accessibility globally.
Artificial Intelligence (AI)
AI is arguably the most significant driver of change in healthcare today. From predictive analytics to robotic surgeries, AI technologies are enhancing the capabilities of healthcare providers and improving patient outcomes.
Many tech giants are entering the healthcare space, modeling strength in technology. Some are here to stay, but some are already facing ongoing challenges and pulling back.
Investors are particularly enthusiastic about AI's potential to automate repetitive tasks in healthcare settings, such as insurance processing and patient scheduling, which can significantly reduce costs and improve efficiency. However, it is getting much attention from unsophisticated investors who need help understanding the healthcare paradigm and AI-associated issues.
Preetha Ram [Managing Partner, INpact Fund and CTO, Pier 70 Ventures] mentions, “Automation in tasks like insurance processing and clinical diagnostics are low-hanging fruits that AI is effectively addressing, reducing costs and improving service delivery.”
We're in a complex stage of integrating AI into healthcare, often viewed as a "black box" due to its opaque decision-making. AI has great potential to manage large datasets and deliver rapid insights but struggles with the nuances of human behavior. A key issue is AI's difficulty interpreting medical data influenced by personal biases and cultural backgrounds, often missing the deeper meanings that a human doctor would understand. Currently, AI relies heavily on the explicit information provided.
Ali Pashazadeh [Founder, Treehill Partners]: For AI to be more effective in clinical settings, it must evolve to process large quantities of data and critically analyze the context and veracity of that data in real time.
The integration of AI in healthcare is promising. Still, advancements in natural language processing, understanding of cultural nuances, and ethical considerations are required to ensure that AI effectively complements medical practice's human elements.
Medical Devices
The medical devices sector is experiencing a shift towards minimally invasive devices that are highly integrated with digital health platforms.
Rachna Dayal [Managing Partner, Sugati Ventures] points out the trends towards “miniaturization and closed loop control,” which enhance the usability and functionality of these medical devices in remote care settings.
The medtech segment has been experiencing a resurgence in FDA approvals, with a record number of novel medical technologies approved in 2023. This trend is driven by advancements in AI, miniaturization, and digitally enabled devices such as neuromodulation and robotics (McKinsey & Company).
Digital Health and Digital Therapeutics
The digital health sector continues to attract significant investment, driven by the proliferation of health apps and telemedicine platforms. However, the excitement around digital health comes with challenges and exceptional regulatory hurdles. There is a slowdown in investment in digital health due to challenges in generating returns from consumer health solutions, which require high user retention and engagement.
The Digital Therapeutics sector is gaining traction as an effective complement to more traditional treatment pathways, particularly in managing chronic diseases and mental health. Some Digital therapeutics companies focused on female health are also doing very well. Just this week, Curio Therapeutics got FDA approval for their post-partum depression app.*
Rachna Dayal [Managing Partner, Sugati Ventures] observes, “Investment in digital therapeutics is growing as these solutions demonstrate their ability to improve patient outcomes and reduce overall healthcare costs.”
Genomics and Health Tech
Advancements in genomics are paving the way for highly personalized medicine. This technology enables the development of treatments tailored to individual genetic profiles, revolutionizing areas such as cancer treatment and rare disease management.
This approach enhances the effectiveness of treatments and reduces the risks and side effects associated with traditional one-size-fits-all therapies.
Alicia Castillo Holley [GP/Founder, Wealthing VC Fund] highlights that even with higher initial costs, personalized medicine can be more cost-effective in the long term because it avoids ineffective treatments.
Wearables and Consumer Behavior
The future belongs to the empowered consumer-patient, where the distinction between consumer and patient is increasingly blurred. As people become more health-conscious and adept with technology, their preferences shape the development of personalized health solutions. These solutions range from wearable technologies that monitor health metrics to apps that promote proactive health management and patient-centric service models tailored to individual needs. Consumers demand greater transparency and personalization from their care providers regarding treatments and medications.
As Rashmi Rao [Managing Director, rcubed|ventures] observes, “I see the consumer-patient demanding more from their care providers in terms of context and background regarding medications, treatment plans that are personalized and tailored. Understanding these trends helps investors identify promising opportunities in consumer-driven health innovations.”
Wearables in healthcare are transforming patient monitoring and disease management. Devices like smartwatches and fitness bands track vital signs, activity levels, and sleep patterns, providing real-time data to both patients and physicians. These wearables are also integral to decentralized trials and of interest to investors. This technology enhances preventive medicine and personalized care, significantly improving health outcomes.
Health and wellness companies do B2C and gather data to show to Payers for reimbursement. In this case, consumer adoption is of the utmost importance.
In the era of patient-reported outcomes, wearables have a special place.
Venture Capital in Healthcare
Venture capital plays a critical role in enabling the growth and adoption of innovative healthcare technologies. Investors mainly focus on startups that promise technological innovation and demonstrate widespread adoption and profitability potential.
In 2023, transaction volumes in the life sciences and healthcare sectors decreased from the previous year's levels. Life sciences deals fell from 1,133 to 919, while healthcare transactions dropped from 1,001 to 857, with much of this decline occurring in the fourth quarter. Strategic investment in life sciences companies declined, with deals dropping from 778 in 2022 to 662 in 2023. However, healthcare transactions by strategic investors experienced growth, increasing from 475 in 2022 to 566 in 2023. Biopharma services continue to attract significant attention from private equity, with firms actively investing in drug development and manufacturing outsourcing (PMG).
VC-backed companies like My Health Teams bring together consumers based on their health issues to form a collective voice to influence pharmaceutical companies' research and development practices. Originally intended to facilitate a unified consumer presence within the healthcare industry, the company has found its role as a mediator between consumers and pharma. However, the broader goal of uniting consumers across America for healthcare advocacy has proven challenging.
Focus Areas for VC Firms
Venture capital firms are particularly interested in healthcare IT companies that leverage AI and big data to improve healthcare delivery, cost efficiency, and patient outcomes (Visible.vc). Additionally, there's a growing emphasis on healthcare services and digital health platforms that integrate advanced technologies to enhance care coordination and patient engagement (Visible.vc).
VC firms investing in AI-based startups look at Data, quality, compatibility, and a realistic capital ask that accounts for talent, data cleansing, mining, and other hurdles.
In my discussions, the investors were interested in companies like Acclinate(Clinical Trial Diversity and Diversity in Healthcare), Waverly (Diagnostic Solutions), Midi Health (Women's Health for 40+ women), and MedTech companies in nanomaterials.
Strategic investments that align with comprehensive regulatory frameworks and societal needs will be crucial in realizing the full potential of next-generation healthcare solutions. This approach fosters innovation, ensures patient safety and privacy, and addresses healthcare disparities.
The insights industry experts provide underscores the healthcare sector's dynamic and multifaceted nature. As technology advances and investment strategies evolve, the fundamental goal remains clear: to enhance healthcare outcomes and accessibility for all population segments, paving the way for a healthier future.
It is crucial for discernment in investments, especially in a post-pandemic era where the focus shifts from quantity to quality of innovation. Investors are increasingly looking at startups' long-term viability and regulatory compliance rather than just the novelty of the technology. This trend includes investments in startups like Tempus, a leader in artificial intelligence and precision medicine (founded in 2015), which, on Jan 24th, 2024, announced that the company had signed agreements for in-network provider status with Humana Inc. Humana has over 13 million members who'll now have Tempus' portfolio of molecular profiling tests by their medical policies, expanding precision oncology care throughout the country.
Investment Trends
Venture capitalists do not just fund companies; they are increasingly involved in shaping their strategies and growth paths. The importance of collaboration and resource-sharing in the health sector is akin to how companies like Uber optimize asset utilization without owning it.
As Preetha Ram [Managing Partner, INpact Fund and CTO, Pier 70 Ventures] notes, “FDA’s evolving guidelines are accelerating the approval of AI and digital health applications, significantly impacting investment strategies. Just last year alone, the FDA cleared 700 AI healthcare algorithms, more than 76% of the radiology space.”
VCs are keenly interested in areas that combine technological innovation with significant market needs.
Terri Hanson Mead [Angel investor] comments on the investment trends, noting, “While digital health investment saw a slowdown due to poor consumer retention impacting returns, there is no denying the sector’s potential to revolutionize healthcare.”
A few areas where investments are projected in the next five years are:
Predictive and Preventive Medicine
Using big data and analytics to predict health trends and prevent diseases before they occur is becoming increasingly feasible and valuable. This approach promises to reduce healthcare costs and improve quality of life, presenting a lucrative area for venture capital investment.
Robotics and Automation in Surgery
Robotic technologies are making surgeries less invasive and more precise, improving patient outcomes and reducing hospital stays and healthcare costs, making it a growing investment focus.
Virtual Reality (VR) and Augmented Reality (AR)
These technologies can transform medical training and patient care delivery, offering immersive experiences that enhance understanding and improve surgical precision.
Other Therapeutic Areas
- Women's Health
- ADC (Antibody Drug Conjugates)
- Obesity
- Liver (a resurgence)
- Radionuclides
Alicia Castillo Holley [GP/Founder, Wealthing VC Fund] emphasizes the strategic importance of investment in women’s health, a previously underfunded area now recognized for its market potential. “There is a blue ocean opportunity in women’s health, given that it affects half of the population yet has been historically underserved,” she notes.
Criteria for Investment
Investors look for startups with innovative solutions, a clear path to market, and a scalable business model. Navigating regulatory landscapes remains a significant hurdle for healthcare startups. Increasingly, investors prioritize understanding the regulatory landscape for their investments before committing funds.
The venture healthcare landscape faces challenges such as regulatory complexities and high initial costs associated with personalized medicine. However, the long-term benefits, such as more effective treatments and reduced healthcare costs, justify these investments.
Preetha Ram [Managing Partner, INpact Fund and CTO, Pier 70 Ventures] emphasizes the importance of proprietary data and compliance strategies for gaining investor confidence. “Companies need to demonstrate how they handle data privacy and regulatory challenges to attract serious capital,” she asserts.
Investors remain cautious due to economic uncertainties and regulatory environments, which can influence funding dynamics and investment strategies (Crunchbase news). Nevertheless, strategic acquisitions and partnerships are increasingly viewed as vital for growth and innovation in the sector (KPMG).
Terri Hanson Mead [Angel investor] elaborates, “We are seeing a lot of naive investments in the health tech sector by investors unfamiliar with the complexities of healthcare regulations and patient care requirements.”
Emerging Markets and Global Opportunities
Emerging markets, particularly in Asia and Africa, are becoming hotspots for healthcare innovation. This is driven by increasing local demand for healthcare services and the rise of local entrepreneurs. Investors keenly observe these regions for growth opportunities, where technological innovations can leapfrog existing healthcare infrastructure.
Potential regions like Korea, Europe, and Australia are up-and-coming in the global healthcare investment landscape. South Korea is recognized as a burgeoning center of scientific innovation, particularly noted for its advancements in early-stage scientific research. However, these innovations need to be advanced beyond early clinical trials.
As Ali Pashazadeh [Founder, Treehill Partners] comments, while Korea produces a significant amount of promising science, particularly up to Phase I and the beginning of Phase II of clinical trials, it often struggles with the subsequent stages, which require a different set of skills — shifting from the rigid frameworks of scientific research to the more nuanced, decision-driven processes of later-stage clinical development.
This transition can be likened to moving from a purely scientific approach to one that incorporates elements of 'art,' where strategic and practical decisions about patient selection and trial design become crucial. In South Korea, there appears to be a bottleneck at this critical juncture due to a need for more expertise and experience in meeting the nuanced demands of Phase II and beyond.
Similarly, Australian companies demonstrate strong potential in early clinical phases but often stall at the Phase 2a stage, struggling with market access and the strategic direction necessary to progress further in the clinical pipeline. This stagnation at critical transition points highlights a global challenge in the biotech industry. While scientific prowess is crucial, the ability to navigate the complexities of clinical trials and market strategies is equally important to bring scientific advancements to fruition.
Social Impact and Sustainability in Healthcare Investments
An emerging trend in healthcare venture capital is the emphasis on social impact and sustainability. Investors are increasingly considering the broader societal benefits of their investments, aligning with global shifts towards responsible investing. For instance, companies like Acclinate and Wavely are leveraging technology to address healthcare disparities and improve healthcare systems' cost efficiencies, attracting investors interested in financial returns and social impact.
Alicia's portfolio companies even have a Social Multiplier Factor as an evaluation criterion.
Investors increasingly recognize the importance of inclusivity and diversity in healthcare innovations. Venture capital should support solutions that cater to a broad spectrum of society, not just affluent segments. This approach prevents technologies like AI from reinforcing existing biases if not appropriately controlled.
Terri Hanson Mead [Angel investor] discusses the need for investments to have a social multiplier effect. “We look for companies that promise technological innovation and do not negatively impact our planet and members of our society. It’s never ROI at all costs,” she explains.
This approach is visible in the growing popularity of impact investing in the healthcare sector, where funds like the Global Health Investment Fund are directing capital toward innovations that offer market-based returns and public health benefits.
Rashmi Rao [Managing Director, rcubed|ventures] comments, “There is a wealth of expertise in individual sectors such as technology, health, agriculture, pharmaceuticals, B2B SaaS, and AI; a critical knowledge gap exists in the intersection of these sectors. This gap presents significant challenges for companies operating in these spaces, impeding their ability to scale effectively. This is also the opportunity for investors and founders to solve these critical gaps.”
Investors also focus on sustainability and social impact, assessing how healthcare innovations can benefit underrepresented communities or address widespread health issues like diabetes and cardiovascular diseases, disproportionately affecting specific populations.
The Road Ahead: Strategic Investments and Integrated Healthcare Solutions
As we look to the future, the healthcare industry is poised for significant evolution, driven by technological innovation and complex investment dynamics. The integration of AI and personalized medicine is set to redefine patient care standards. At the same time, venture capital is crucial in steering these innovations to market readiness and widespread adoption.
Using AI and technology to improve healthcare staff training and associated services, reduce errors, and reduce new worker burnout will ensure reduced churn out of healthcare staff.
The future of healthcare will be characterized by a nuanced blend of technological prowess, strategic venture capital, and an unwavering commitment to societal welfare. This holistic approach will drive innovation and ensure that modern healthcare's benefits are equitably distributed, marking a new era of healthcare that is as compassionate as it is innovative.
Ali Pashazadeh [Founder, Treehill Partners] — I think 85% of the companies that we see are companies that not only need capital, but they need capabilities. They are not at a stage where they have the capabilities to accept the capital and deliver on what the investor would want.
Today, funds are likely to invest in companies only if they already possess the necessary capabilities or if the fund can provide these capabilities, akin to the private equity model of the 1980s. There is currently a backlog of companies aiming to go public within the next three years, and there are enough companies to sustain five years of activity if they receive the necessary capital to hire and develop the required expertise for later-stage development.
Conclusion
The future of healthcare is intricately linked to technological innovation and strategic venture investment. As these trends evolve, they promise to deliver more personalized, efficient, and accessible healthcare solutions across the globe, fundamentally altering the healthcare landscape in the years to come. Investors, while optimistic, remain cautious, navigating the complex interplay of technological potential and regulatory frameworks to find sustainable and impactful investment opportunities.
HLWF ™ Alliance
No more silos, just solutions! | Interdisciplinary outcomes uniting healthcare and wellness practices.
Our community of women leaders, health heroes and wellness wizards take a holistic view working on the intersections of health and wellbeing — join us at HLWF ™ Alliance.
